Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine

A technology of triptolide and triptolide ester is applied in the application field of triptolide derivatives in the treatment and preparation of antitumor drugs, and can solve the problem of finished medicines without taking relevant consideration and ignoring the water solubility of triptolide problems, etc., to achieve the effect of being conducive to quality control, improving pharmacokinetic properties, and improving water solubility

Active Publication Date: 2012-05-02
ZHEJIANG UNIV OF TECH
View PDF8 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The Chinese patent with publication number CN 101311187A discloses a long-chain alcohol ester of tripterygium wilfordii and its preparation method and application. But this patent ignores the water-solubility of tripterygne, and does not consider the problem of making medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine
  • Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine
  • Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Synthesis of tripterine derivative CLS-1 (synthesis route as shown in Figure 1)

[0033] Dissolve 72.8 mg of triphosgene (BTC) (0.24 mmol) in 2 mL of dichloromethane (DCM), add dropwise 1 mL of 0.35 mol / L morpholine (0.35 mmol) dichloromethane solution and 100 μL of triethyl Amine (0.99mmol), stirred at room temperature for 1h, then added dropwise 1mL tripterine (0.2mmol) dichloromethane solution with a concentration of 0.2mol / L, continued to stir for 24h, stopped the reaction, added 15mL deionized water, ethyl acetate Extract 4mL*3 times, combine the organic layers, wash with saturated NaCl solution 4mL*3 times, anhydrous NaCl 2 SO 4 Drying, suction filtration, the filtrate was concentrated to obtain a dark red oily crude product, and then the crude extract was eluted by flash column chromatography with a mixed solvent of n-hexane:acetone volume ratio of 3:1 as the eluent, and spot plate Detect (developing agent petroleum ether: acetone=2: 1; Rf value 0.38...

Embodiment 2

[0038] Synthesis of embodiment 2 tripterine derivatives CLS-2 (synthetic route diagram as shown in Figure 1)

[0039] Dissolve 72.8 mg of BTC (0.24 mmol) in 2 mL of dichloromethane (DCM), add 1 mL of 0.35 mol / L N-methylpiperazine (0.35 mmol) dichloromethane solution and 100 μL of triethyl ether dropwise under ice cooling Amine (0.99mmol), stirred at room temperature for 1h, then added 1mL tripterine (0.2mmol) dichloromethane solution with a concentration of 0.2mol / L, continued to stir for 24h, then stopped the reaction, added 15mL deionized water, extracted with ethyl acetate 4mL*3 times, combined organic layer, washed with saturated NaCl solution 4mL*3 times, anhydrous NaCl 2 SO 4 Drying, suction filtration, and concentration to obtain a dark red oily crude product, then the crude extract was eluted by flash column chromatography with a mixed solvent of n-hexane: acetone volume ratio of 3: 1 as eluent, and spot plate detection ( Developing agent sherwood oil: acetone=2: 1; ...

Embodiment 3

[0040] Example 3 Synthesis of tripterine derivatives CLS-3 (synthesis route as shown in Figure 1)

[0041] Dissolve 72.8 mg of triphosgene BTC (0.24 mmol) in 2 mL of dichloromethane (DCM), add dropwise 1 mL of 0.35 mol / L N-ethylpiperazine (0.35 mmol) in dichloromethane solution and 100 μL of Triethylamine, stirred at room temperature for 1h, then added dropwise 1mL of tripterine (0.2mmol) dichloromethane solution with a concentration of 0.2mol / L, continued to stir for 24h, then stopped the reaction, added 15mL of deionized water, and extracted 4mL with ethyl acetate *3 times, combine the organic layers, wash with 4mL of saturated NaCl solution*3 times, anhydrous NaCl 2 SO 4Drying, suction filtration, and concentration to obtain a dark red oily crude product, then the crude extract was eluted by flash column chromatography with a mixed solvent of n-hexane: acetone volume ratio of 3: 1 as eluent, and spot plate detection ( Developing agent sherwood oil: acetone=2: 1; Rf value ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to celastrol, a celastrol derivative, a method for preparing the celastrol derivative, biogenetic salt prepared from the celastrol derivative serving as a raw material, and application of the celastrol derivative to the preparation of an antitumor medicine. The celastrol derivative has a structure shown as a formula I, wherein R1 is H, C1-C6 straight-chain or branched-chain alkyl, benzyl and benzyl with a substituent group on a benzene ring; and R2 or R3 are independent C5-C6 cyclic hydroxyl, C1-C6 chain alkyl, phenyl and substituted phenyl respectively, or R2 and R3 are cyclized with N, and the cycle is hexahydric cyclic heterocycle containing N or O. The celastrol derivative has high antitumor activity, stability and water solubility. The celastrol derivative can be salified with one of medically acceptable inorganic acids (such as hydrochloric acid, sulfuric acid and phosphoric acid) or organic acids (citric acid, cinnamic acid, succinic acid and the like); and the salt has high water solubility.

Description

(1) Technical field [0001] The present invention relates to the preparation method of tripterygne and its derivatives and tripteryne derivatives, also relates to the biological salt prepared from tripteryne derivatives as raw materials, and tripteryne derivatives in the preparation of anti-tumor drugs in the application. (2) Background technology [0002] Malignant tumors seriously endanger people's health. According to WHO statistics, among the more than 5 billion people in the world, 6.9 million people die from malignant tumors every year on average, and 8.7 million new cases occur, and the number is still increasing year by year. Antineoplastic drug therapy is one of the main methods of cancer treatment. Natural products are a treasure trove for discovering new antineoplastic drugs. The lead compounds of many antineoplastic drugs are obtained from nature, such as vinblastine, vincristine, camptothecin, Paclitaxel, etc., but these natural compounds often require structura...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07J63/00A61P35/00A61P1/16
Inventor 单伟光占扎君张丽雯温彦涛陈艳王建伟唐岚于海宁侯晓蓉
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap